These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 17038885)

  • 1. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
    Yang CG; Ciccolini J; Blesius A; Dahan L; Bagarry-Liegey D; Brunet C; Varoquaux A; Frances N; Marouani H; Giovanni A; Ferri-Dessens RM; Chefrour M; Favre R; Duffaud F; Seitz JF; Zanaret M; Lacarelle B; Mercier C
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):49-56. PubMed ID: 20204365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
    Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R; Chaussade S
    Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Yen JL; McLeod HL
    Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
    Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
    Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
    Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
    Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
    Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
    Lazar A; Jetter A
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.